The Institute of Human Stem Cells attracted 155 million rubles for the development of vaccines
The developer of vaccines, the biotech company DBT (Development of Biotechnologies) of the Human Stem Cell Institute (HSCI) group, raised 155 million rubles during a private placement on the Rounds investment platform, the HSCI press center reports.
DBT planned to attract from 50 to 160 million rubles. Placement passed on the upper border, with oversubscription. The book of applications from investors wishing to take part in the company's first investment round has reached more than 251 million rubles. In the process of formalizing transactions by investors, as well as Skolkovo Foundation benefits, only a part of the applications were satisfied. 860 investors became shareholders of the company. With the opportunity to receive a benefit from the Skolkovo Foundation (reimbursement of up to 50% of the investment amount), 59 people invested in the DBT in the amount of 110 million rubles.
According to Igor Krasilnikov, Director of DBT: “The placement was successful thanks to the HSCI ecosystem and investor support from Skolkovo. This is a good example of the fact that investors in Russia have an interest in biotech. And biotech for its development is able to attract investments in the venture capital market. Investments are planned to be used to expand the portfolio of DBT developments.”
Vladimir Egorov, Operations Director of the Biomedical Technologies Cluster of the Skolkovo Foundation: “HSCI is an official partner of the Skolkovo Foundation, developing a number of promising projects in the field of high-tech medicine at the Innovation Center: gene therapy, cell technologies and vaccines. Thanks to our cooperation, we can expand and improve the mechanisms for supporting innovative companies. The RBT placement was the first experience of raising funds using an investment platform with the possibility of further receiving reimbursement through our program. RBT already has a good portfolio of products at various stages of readiness today, and their vaccine development platform has significant potential to expand it.”